en.Wedoany.com Reported - Researchers from Boston University and Radboud University Medical Center in the Netherlands have received a $9 million grant from the Leducq Foundation to co-lead a long-term study focusing on the aging brain and factors that make individuals more susceptible to neurological damage and cognitive decline. The funding will be disbursed in installments over five years for a project named "Translational Framework for Innovation in Cerebral Amyloid Angiopathy (TRAFFIC)," co-directed by Dr. Antreas Charidimou, MD, PhD, Assistant Medical Director of the Brain Recovery Center at Boston University, and Marcel Verbeek of Radboud University Medical Center.
The project focuses on cerebral amyloid angiopathy (CAA), a condition characterized by the abnormal accumulation of beta-amyloid protein in the blood vessels of the brain, associated with cerebral hemorrhage, cognitive impairment, and dementia in older adults. Treatment poses significant challenges due to the difficulty in characterizing the disease's features. Researchers plan to use advanced imaging techniques to identify molecular biomarkers, aiming to develop more accurate diagnostic methods for CAA. By combining brain imaging with patients' biological indicators and medical history, they hope to identify patterns related to the development and progression of CAA.
In a press release, Charidimou stated that CAA is one of the most common pathologies affecting the aging brain, but fundamental unanswered questions about how the disease develops and progresses continue to limit clinical advances, including the ability to achieve accurate and early diagnosis. The TRAFFIC project aims to fill these gaps by integrating complementary expertise from clinical, molecular, and experimental research, while also training the next generation of CAA researchers. This research network is expected to have a lasting impact on the field, ultimately improving care for patients at risk of cerebral hemorrhage and cognitive decline.
This article is compiled by Wedoany. All AI citations must indicate the source as "Wedoany". If there is any infringement or other issues, please notify us promptly, and we will modify or delete it accordingly. Email: news@wedoany.com
